Badania kliniczne w Polsce

Drogie Koleżanki i Koledzy, Członkowie Polskiego Towarzystwa Onkologicznego,

Z prawdziwą przyjemnością chciałbym Państwa poinformować o kolejnej, inicjatywie naszego Towarzystwa. Na stronie internetowej PTO zamieściliśmy bazę prowadzonych w Polsce badań klinicznych w zakresie onkologii, dostępnych publicznie w rejestrze Narodowego Instytutu Raka w USA (National Cancer Institute – NCI).

Liczymy, że informacje zawarte w bazie ułatwią komunikację pomiędzy badaczami i ośrodkami, oraz będą stanowiły źródło wiedzy dla lekarzy i chorych zainteresowanych prowadzonymi w Polsce badaniami klinicznymi.

Badania umieszczone w bazie będą aktualizowane raz w miesiącu. Będziemy również umieszczali uzupełnienia danych na życzenie realizujących je badaczy.

Baza może być przeglądana na różne sposoby, poprzez ustawienie filtrów numeru badania, jego tytułu, wskazania, rodzaju chorych, fazy badania lub jego sponsora. Możliwe jest także przeglądanie ośrodków prowadzących poszczególne badania. Dzięki aktywnym linkom, będzie można łatwo przenieść się do danych źródłowych i zapoznać z pełnymi informacjami o badaniu, zawartymi w protokole.

Liczymy, że wartość informacyjna takiej bazy okaże się pomocna w codziennej pracy klinicznej członków naszego Towarzystwa.

Będziemy wdzięczni za przekazywanie nam swoich uwag na adres . Zapraszamy także na naszą oficjalną stronę internetową www.portal-pto.pl, gdzie znajdą Państwo szereg przydatnych informacji.

Prof. Jacek Jassem
Przewodniczący Zarządu Głównego PTO

Nr badania Tytuł badania Nowotwór Kategoria chorych Faza badania Sponsor Data rozpoczęcia Planowana data zakończenia Ośrodki badawcze Linki
D0816C00010 Otwarte, randomizowane, kontrolowane, wieloośrodkowe badanie fazy III mające na celu ocenę skuteczności i bezpieczeństwa monoterapii olaparibem w porównaniu z chemioterapią pojedynczym preparatem wybranym przez lekarza w leczeniu wrażliwego na platynę nawracającego raka jajnika u pacjentek będących nosicielkami mutacji BRCA1/2 komórek linii płciowych (A Phase III, Open Label, Randomized, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients carrying germline BRCA1/2 Mutations/) rak jajnika pacjentki będące nosicielkami mutacji BRCA1/2 komórek linii płciowych III AstraZeneca AB 2015-06 2017-12

1. Gdańsk, Poland, 2. Grzepnica, Poland 3. Lublin, Poland 4. Olsztyn, Poland 5. Poznań, Poland 6. Warszawa, Poland 7. Łódź, Poland

clinicaltrials.gov
NCT02370238 A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA) rak piersi potrójnie ujemny rozsiany kobiety z nawrotem choroby po wcześniejszej terapii (neo)adjuwantowej II Dompé Farmaceutici s.p.a. 2015-06 2016-10

1. Joanna Pikiel, Wojewódzkie Centrum Onkologii Gdańsk (+48 58 345 20 69)

2. Piotr Tomczak, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu (+ 48 61 854 90 38)

3. Tomasz Sarosiek, Magodent Sp. z o. o. Warszawa (+48 22 430 89 20)

4. Marek Wojtukiewicz, Białostockie Centrum Onkologii im. Marii Skłodowskiej – Curie (+48 85 664 67 34)

5. Andrzej Mruk, Mrukmed. Lekarz Beata Madej Mruk i Partner. Spółka Partnerska Oddział nr 1 w Rzeszowie (+48 17 853 07 28)

6. Bożena Kukiełka-Budny, Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli (+48 81 454 1002)

clinicaltrials.gov
NCT02111577 A Randomized, Double Blind, Multicenter, Parallel-Group,Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy rak gruczołu krokowego przerzutowy rak gruczołu krokowego oporny na kastrację III SOTIO 2014-01 2016-12

Łódź, Warszawa, Wrocław, Lublin

clinicaltrials.gov/ct2/show/NCT02111577
www.sotio.com
KF6005/07 Efficacy, safety, and tolerability of oral cebranopadol versus morphine sulfate PR in subjects with chronic moderate to severe pain related to cancer (Skuteczność, bezpieczeństwo i tolerancja doustnego cebranopadolu w porównaniu z siarczanem morfiny o przedłużonym uwalnianiu (PR) u pacjentów z przewlekłym bólem związanym z rakiem o nasileniu od umiarkowanego do ciężkiego) Pacjentów z przewlekłym bólem związanym z rakiem o nasileniu od umiarkowanego do ciężkiego III Grünenthal GmbH 2013-09 2016-04

Włocławek ,Gdynia, Gdańsk, Wrocław, Warszawa ,Gliwice ,Czeladź ,Dąbrowa Górnicza ,Bydgoszcz

NCT02152631 A Study of Abemaciclib (LY2835219) in Participants With Previously Treated Lung Cancer rak płuca KRAS+ III Lilly 2014-10 2016-12

Gdańsk, Łódź, Olsztyn, Radom, Szczecin

clinicaltrials.gov/show/NCT02152631
NCT02149108 Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer rak jelita grubego oporny III Boehringe-Ingelheim 2014-09 2016-07

Poznań

clinicaltrials.gov/show/NCT02149108
NCT02138422 A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer rak jelita grubego oporny III XBiotech 2014-07 2015-09

Warszawa

clinicaltrials.gov/show/NCT02138422
NCT02107703 A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer rak piersi HER2- ER+ III Lilly 2014-07 2020-02

Gdańsk, Łódź, Wieliszew, Białystok

clinicaltrials.gov/show/NCT02107703
NCT02106546 Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer rak płuca płaskonabłonkowy III AbbVie 2014-04 2016-11

Gdynia, Rzeszów, Warszawa, Wieliszew

clinicaltrials.gov/show/NCT02106546
NCT02075840 ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients rak płuca ALK+ III Roche 2014-08 2017-12

Gdańsk, Lublin, Olsztyn, Otwock, Poznań, Warszawa

clinicaltrials.gov/show/NCT02075840
NCT02049905 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas mięsaki >15 r.ż. III CytRx 2014-01 2018-02

Warszawa

clinicaltrials.gov/show/NCT02049905
NCT02041533 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) rak płuca stopień IV III BMS 2014-03 2018-01

Bydgoszcz, Kraków, Łódź, Wodzisław ŚląskiWarszawa

clinicaltrials.gov/show/NCT02041533
NCT02032823 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer rak piersi HER2- III AstraZeneca 2014-04 2028-02

Gdańsk, Łódź, Olsztyn, Poznań, Warszawa

clinicaltrials.gov/show/NCT02032823
NCT02031432 CORAL XT - Open-label Extension Trial of the CORAL Trial różne nowotwory leczenie przeciwbólowe III Grunenthal 2013-12 2016-09

Będzin, Dabrowa Górnicza, Gdańsk, Gliwice

clinicaltrials.gov/show/NCT02031432
NCT02017717 A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) glejak stopień IV III BMS 2014-01 2018-01

Gdańsk, Warszawa

clinicaltrials.gov/show/NCT02017717
NCT02008227 A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK rak płuca platynooporny III Roche 2014-03 2017-06

Gdańsk, Łódź, Poznań, Warszawa

clinicaltrials.gov/show/NCT02008227
NCT02003924 Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer rak gruczołu krokowego podczas ADT III Astellas 2013-12 2017-08

Gdańsk, Mysłowice, Słupsk, Warszawa, Wrocław

clinicaltrials.gov/show/NCT02003924
NCT02000622 Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. rak piersi BRCA1 , BRCA2 III AstraZEneca 2014-03 2018-12

Elbląg, Gdańsk, Łódź, Olsztyn, Poznań, Tarnobrzeg, Warszawa

clinicaltrials.gov/show/NCT02000622
NCT01989676 A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) rak piersi przerzutowy HER2+ III Pfizer 2014-02 2016-10

Gdańsk, Gdynia, Rzeszów, Warszawa

clinicaltrials.gov/show/NCT01989676
NCT01974440 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin chłoniak iNHL B-komórkowy III Janssen 2014-01 2021-08

Gdynia, Olsztyn, Warszawa

clinicaltrials.gov/show/NCT01974440
NCT01966471 A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer rak piersi ajuwant III Roche 2014-01 2024-01

Gdańsk, Kraków, Lublin, Warszawa

clinicaltrials.gov/show/NCT01966471
NCT01966003 Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer rak płuca zaawansowany III Amgen 2013-11 2016-02

Bydgoszcz, Elbląg, Mrozy, Olsztyn, Rzeszówm, Szczecin, Toruń, Warszawa

clinicaltrials.gov/show/NCT01966003
NCT01964378 CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer różne nowotwory leczenie przeciwbólowe III Grunenthal 2013-11 2016-04

Będzin, Bydgoszcz, Chorzó∑, Dąbrowa, Elbląg, Gdańsk, Gliwice, Kraków, Warszawa, Włocławek, Wrocław, Żory

clinicaltrials.gov/show/NCT01964378
NCT01946204 A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer rak gruczołu krokowego III Aragon 2013-10 2019-08

Białystok, Bydgoszcz, Gdańsk, Kutno, Łódź, Otwock, Poznań, Szczecin, Toruń, Warszawa, Wrocław

clinicaltrials.gov/show/NCT01946204
NCT01945775 A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) rak piersi BRCA+ III BioMarine 2013-10 2016-06

Gliwice, Łódź, Otwock

clinicaltrials.gov/show/NCT01945775
NCT01938001 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) chłoniak oporny III Celgene 2013-09 2021-12

Kraków, Warszawa

clinicaltrials.gov/show/NCT01938001
NCT01933932 Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC rak płuca KRAS+ III AstraZeneca 2013-09 2017-03

Bydgoszcz, Gdańsk, Kraków, Lublin, Olsztyn, Opole, Sucha Beskidzka, Szczecin, Tarnów, Warszawa

clinicaltrials.gov/show/NCT01933932
NCT01909453 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma czerniak BRAF+ III Novartis 2013-09 2018-03

Warszawa

clinicaltrials.gov/show/NCT01909453
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib rak wątrobowokomórkowy po sorafenibie III Exelixis 2013-08 2016-10

Mysłowice, Olsztyn Poznań

clinicaltrials.gov/show/NCT01908426
NCT01905592 A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients rak piersi HER2- BRCA1 III Tesaro 2013-10 2016-03

Łódź, Racibórz

clinicaltrials.gov/show/NCT01905592
NCT01901146 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer rak piersi wczesny HER2+ III Amgen 2013-04 2016-12

Bydgoszcz, Gdańsk, Rybnik, Poznań, Rzeszów, Warszawa

clinicaltrials.gov/show/NCT01901146
NCT01855750 A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma chłoniak wielkokomórkowy III Janssen 2013-09 2020-06

Brzozów, Chorzów, Kraków, Olsztyn, Poznań, Warszawa, Wrocław

clinicaltrials.gov/show/NCT01855750
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer rak jajnika LGS III Array 2013-06 2016-06

Szczecin

clinicaltrials.gov/show/NCT01849874
NCT01847274 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer rak jajnika gBRCAmut III Myriad 2013-06 2016-10

Białystok, Gdańsk, Łódź, Poznań

clinicaltrials.gov/show/NCT01847274
NCT01843062 Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer rak tarczycy zróżnicowany III AstraZeneca 2013-08 2018-03

Gliwice, Kielce, Poznań, Warszawa, Zgierz

clinicaltrials.gov/show/NCT01843062
NCT01828099 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer rak płuca ALK+ nieleczeni III Novartis 2013-07 2018-06

Gdańsk, Konin, Szczecin, Warszawa

clinicaltrials.gov/show/NCT01828099
NCT01798485 A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC rak płuca zaawansowany III Synta 2016-03 2016-03

Kraków, Olsztyn, Poznań, Prabuty, Szczecin, Warszawa

clinicaltrials.gov/show/NCT01798485
NCT01782131 A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069/P06200) różne nowotwory leczenie wspomagające III Merck 2013-09 2017-10

Warszawa

clinicaltrials.gov/show/NCT01782131
NCT01777152 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas chłoniak komórki T III Millenium 2013-01 2019-12

Brzozów, Chorzów, Gliwice, Kraków, Warszawa

clinicaltrials.gov/show/NCT01777152
NCT01774786 A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer rak żołądka , wpustu HER2+ gruczolakorak III Roche 2013-06 2022-03

Bydgoszcz, Kraków, Warszawa

clinicaltrials.gov/show/NCT01774786
NCT01774721 ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. rak płuca zaawansowany III Pfizer 2013-04 2017-02

Gdańśk, Olsztyn, Poznań, Warszawa

clinicaltrials.gov/show/NCT01774721
NCT01767155 Study Comparing AEZS-108/ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) to Doxorubicin as a Second Line Therapy of Endometrial Cancer rak endometrium zaawansowany III Aeterna Zentaris 2013-04 2015-12

Białystok, Łódź, Lublin, Olsztyn, Warszawa

clinicaltrials.gov/show/NCT01767155
NCT01763164 Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma czerniak NRAS+ III Novartis 2013-06 2017-03

Warszawa

clinicaltrials.gov/show/NCT01763164
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma rak wątrobowokomórkowy nieoperacyjny III Eisai 2013-03 2016-04

Gdańsk, Warszawa, Wrocłąw

clinicaltrials.gov/show/NCT01761266
NCT01732926 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas chłoniak iNHL B-komórkowy III Gilead 2013-01 2022-09

Gdańsk, Kraków, Łódź, Lublin, Słupsk, Olsztyn, Warszawa

clinicaltrials.gov/show/NCT01732926
NCT01732913 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas chłoniak iNHL B-komórkowy III Gilead 2013-01 2023-10

Kraków, Lublin, Olsztyn, Warszawa

clinicaltrials.gov/show/NCT01732913
NCT01712490 Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma chłoniak Hodgkina nieleczeni III Millenium 2012-11 2020-03

Gdańsk, Katowice, Kraków, Łódź, Olsztyn, Warszawa

clinicaltrials.gov/show/NCT01712490
NCT01704716 High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN) neuroblastoma 1 m.ż-21 r.ż. III SIOPEN 2012-02 2016-09

Białystok, Bydgoszcz, Chorzów, Kraków, Gdańsk, Katowice, Lublin, Poznań, Warszawa, Wrocław

clinicaltrials.gov/show/NCT01704716
NCT01697072 First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma rak żołądka MET+ III Amgen 2012-10 2017-03

Białystok, Elbląg, Gdańsk, Koni, Łódź, Warszawa

clinicaltrials.gov/show/NCT01697072
NCT01682083 A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. czerniak BRAF+ , po resekcji III GSK 2013-01 2015-07

Gdańsk, Poznań, Konin, Warszawa

clinicaltrials.gov/show/NCT01682083
NCT01667419 BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma czerniak BRAF+ III Roche 2012-09 2022-03

Olsztyn, Warszawa, Wrocław, Poznań

clinicaltrials.gov/show/NCT01667419
NCT01633060 A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi rak piersi przerzutowy, HER2- , HR+ III Novartis 2012-10 2017-03

Olsztyn

clinicaltrials.gov/show/NCT01633060
NCT01630733 A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer rak płuca przerzutowy III Teva 2012-09 2017-07

Olsztyn, Poznań

clinicaltrials.gov/show/NCT01630733
NCT01535209 Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection różne nowotwory przerzuty do mózgu III COI Wwa 2012-01 2014-12

Wraszawa, W.Michalski@coi.waw.pl

clinicaltrials.gov/show/NCT01535209
NCT01479244 Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence rak piersi HER2- III Galena 2014-06 2024-06

Gdynia, Łódź, Poznań, Warszawa

clinicaltrials.gov/show/NCT01479244
NCT01450761 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone rak płuca drobnokomórkowy III BMS 2011-12 2017-03

Kraków, Otwock, Toruń, Warszawa

clinicaltrials.gov/show/NCT01450761
NCT01450696 HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer rak żołądka , wpustu HER2+ III Roche 2012-01 2015-12

Warszawa

clinicaltrials.gov/show/NCT01424567
NCT01424566 A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer różne nowotwory leczenie przeciwbólowe III Otsuka 2011-12 2018-05

Bielsko-Biała, Bydgoszcz, Czeladź, Częstochowa, Gdańsk, Gliwice, Kłodzko, Ostrowiec Św., Poznań, Warszawa, Włocławek

clinicaltrials.gov/show/NCT01450696
NCT01419665 GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma chłoniak folikularny CD+ III Novartis 2011-12 2018-03

Brzozów, Chorzów, Kielce, Kraków, Warszawa

clinicaltrials.gov/show/NCT01419665
NCT01345669 LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy rak reg. głowy i szyi III - IVb III Boehringer-Ingelheim 2011-05 2017-12

Poznań, Olsztyn, Warszawa

clinicaltrials.gov/show/NCT01160216
NCT01344018 Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma mięsaki RPS III EORTC 2012-01 2020-01

Warszawa

clinicaltrials.gov/show/NCT01344018
NCT02163694 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer rak piersi HER2- , BRCA1 , 2 III Abbvie 2014-07 2017-01

Elbląg

clinicaltrials.gov/show/NCT02163694
NCT02187744 A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) rak piersi neoadjuwant III Pfizer 2014-09 2016-12

Gdynia

clinicaltrials.gov/show/NCT02187744
NCT01265849 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity rak jamy ustnej pierwotny III Teva 2010-10 2017-12

Białystok, Kielce, łódź, Lublin, Poznań, Warszawa

clinicaltrials.gov/show/NCT01265849
NCT01160211 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer rak piersi HER2+ , ER+ III GSK 2011-05 2017-12

Konin, Warszawa, Wieliszew

clinicaltrials.gov/show/NCT01160211
NCT01077518 Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen chłoniak Hodgkina III GSK 2010-08 2022-05

Gdynia, Opole, Warszawa, Wrocław`

clinicaltrials.gov/show/NCT01077518
NCT00925600 A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy rak gruczołu krokowego leczenie uzupełniające III Amgen 2009-11 2015-07

Gdańsk, Gdynia, Mysłowice, Poznań, Rzeszów, Słupsk, Szcczecin

clinicaltrials.gov/show/NCT00925600
NCT00925600 A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy rak gruczołu krokowego leczenie uzupełniające III Amgen 2009-11 2015-07

Gdańsk, Gdynia, Mysłowice, Poznań, Rzeszów, Słupsk, Szcczecin

clinicaltrials.gov/show/NCT00925600
NCT00883792 The Northern-European Initiative on Colorectal Cancer 55-64 r.ż. III NEICC 2009-05 2036-07

Warszawa

clinicaltrials.gov/show/NCT00883792
NCT00876031 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma mięsaki 0,5-21 r.ż. III UW Tubingen 2009-07 2020-07

Białystok, Bydgoszcz, Gdańsk, Katowice, Kraków, Łódź, Lublin, Szczecin, Warszawa, Wrocłąw

clinicaltrials.gov/show/NCT00876031
NCT00858364 Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy rak płuca leczenie uzupełniające III Amgen 2009-06 2019-06

Bydgoszcz, Głuchołazy, Kraków, Suwałki,Szczecin, Warszawa, Wrocław

clinicaltrials.gov/show/NCT00858364
NCT00833131 The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer rak odbytu nieoperacyjny III PCCSG 2008-11 2015-11

Warszawa W.Michalski@coi.waw.pl

clinicaltrials.gov/show/NCT00833131
NCT00822614 Safety of Fentanyl TAIFUN Treatment różne nowotwory leczenie przeciwbólowe III Akela 2008-12 -

Włocławek

clinicaltrials.gov/show/NCT00822614
NCT00738790 Preoperative Radiotherapy and Local Excision in Rectal Cancer rak odbytu brak przerzutów III PCCSG 2003-11 2013-11

Warszawa W.Michalski@coi.waw.pl

clinicaltrials.gov/show/NCT00738790
NCT00625378 Sorafenib Long Term Extension Program (STEP) rak nerkwo- i wątrobowo-komórkowy kontynuacja III Bayer 2016-07 2016-12

Warszawa

clinicaltrials.gov/show/NCT00625378
NCT00209222 Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL chłoniak kom. pł. nieleczony III GLGGSG 2004-07 2014-12

Warszawa

clinicaltrials.gov/show/NCT00209222
NCT00209209 Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL chłoniak komórki płaszcza III GLGGSG 2004-01 2014-12

Warszawa

clinicaltrials.gov/show/NCT00209209
NCT00081796 Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer rak piersi rozisany III Sanofi 2004-04 -

Kraków, Warszawa

clinicaltrials.gov/show/NCT00081796
NCT01383148 Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer rak płuca ≥ 50% of MUC1 III Transgene 2014-06 2017-05

Olsztyn, Otwock, Poznań, Warszawa

clinicaltrials.gov/show/NCT01383148
NCT01523015 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction rak wpustu operacyjny III AM Lublin 2012-01 2020-12

Lublin

clinicaltrials.gov/show/NCT01523015
NCT01554397 Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer rak szyjki macicy III NCI 2011-09 2017-12

Gliwice

clinicaltrials.gov/show/NCT01554397
NCT01786278 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer rak wpustu operacyjny III AM Lublin 2013-02 2017-12

Lublin

clinicaltrials.gov/show/NCT01786278
NCT01787539 The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer rak żołądka operacyjny III AM Lublin 2013-02 2022-02

Lublin

clinicaltrials.gov/show/NCT01787539
NCT02300389 Randomized, Multi-center Clinical Trial Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated Combined With Androgen Deprivation Therapy in a High Risk Group of Prostate Cancer Patients rak gruczołu krokowego gruczolakorak III WCO 2011-09 2017-12

Olsztyn, Poznań, Wrocław

clinicaltrials.gov/show/NCT02300389
NCT01383148 Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer rak płuca ≥ 50% of MUC1 II Transgene 2012-04 2019-03

Olsztyn, Otwock, Poznań, Warszawa

clinicaltrials.gov/show/NCT01383148
NCT01523015 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction rak wpustu operacyjny II AM Lublin 2012-01 2020-12

Lublin

clinicaltrials.gov/show/NCT01523015
NCT01554397 Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer rak szyjki macicy II NCI 2011-09 2017-12

Gliwice

clinicaltrials.gov/show/NCT01554397
NCT01786278 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer rak wpustu operacyjny II AM Lublin 2013-02 2017-12

Lublin

clinicaltrials.gov/show/NCT01786278
NCT01787539 The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer rak żołądka operacyjny II AM Lublin 2013-02 2022-02

Lublin

clinicaltrials.gov/show/NCT01787539
NCT02300389 Randomized, Multi-center Clinical Trial Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated Combined With Androgen Deprivation Therapy in a High Risk Group of Prostate Cancer Patients rak gruczołu krokowego gruczolakorak II WCO 2011-09 2017-12

Olsztyn, Poznań, Wrocław

clinicaltrials.gov/show/NCT02300389
NCT02273973 A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) rak piersi HER2- , ER+ II BIG 2014-11 2017-07

Gdańsk

clinicaltrials.gov/show/NCT02273973
NCT02161419 RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer rak płuca drobnokomórkowy II Bayer 2014-07 2016-10

Gdańsk

clinicaltrials.gov/show/NCT0216141
NCT02107937 Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma rak jajnika nowozdiagnozowany II Sotio 2013-11 2016-12

Białystok, Kraków, Poznań

clinicaltrials.gov/show/NCT02107937
NCT02107378 Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma rak jajnika nawrotowy II Sotio 2014-01 2016-06

Białystok, Gliwice, Kraków, Lublin, Poznań, Rybnik

clinicaltrials.gov/show/NCT02107378
NCT02093962 Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer rak płuca niepłaskonabłonkowy II Serono 2014-03 2016-10

Otwock, Poznań, Warszawa

clinicaltrials.gov/show/NCT02093962
NCT02087423 A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer rak płuca zaawansowany , przerzutowy II AstraZeneca 2014-02 2016-12

Gdańśk, Warszawa

clinicaltrials.gov/show/NCT02087423
NCT02083653 Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer rak jelita grubego KRAS WT II Serono 2014-03 2016-07

Olsztyn, Poznań, Totuń, Warszawa

clinicaltrials.gov/show/NCT02083653
NCT02052960 CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer rak reg. głowy i szyi EGFR+ II Glycotope 2014-01 2016-12

Bydgoszcz, Kraków, Lublin, Łódź, Warszawa

clinicaltrials.gov/show/NCT02052960
NCT02016534 Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors rózne nowotwory gruczolakorak II Amgen 2014-02 2016-05

Białystok, Elbląg, Konin, Łódź, Warszawa

clinicaltrials.gov/show/NCT02016534
NCT01991210 A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer rak jajnika zaawansowany II Roche 2014-02 2016-06

Białystok, Gdańsk`

clinicaltrials.gov/show/NCT01991210
NCT01935154 Efficacy Study of Vx001 Vaccine in NSCLC Patients rak płuca HLA-A*0201+ II Vaxon Biotech 2012-08 2016-12

Gdańsk, Kraków, Olsztyn, Otwock, Poznań, Szczecin, Warszawa

clinicaltrials.gov/show/NCT01935154
NCT01899599 PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer rak jajnika TA-MUC1+ II Glycotope 2013-09 2017-09

Bydgoszcz, Gdańsk, Lublin, Olsztyn, Rzeszów

clinicaltrials.gov/show/NCT01899599
NCT01852292 Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy rak reg. głowy i szyji nawrotowy , przerzutowy II Novartis 2013-10 2015-11

Warszawa

cinicaltrials.gov/show/NCT01852292
NCT01327612 Open Label Extension Study of Conatumumab and AMG 479 rózne nowotwory kontynuacja II Amgen 2011-03 2014-12

Szczecin

clinicaltrials.gov/show/NCT01327612
NCT01630226 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland rak piersi inwazyjny , BRCA! II PUM , Tomasz Byrski 2007-07 -

Szczecin, tomekbyr@wp.pl

clinicaltrials.gov/show/NCT01630226
NCT01528345 Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer rak piersi HER2- , HR+ II Novartis 2012-04 2015-10

Poznań, Rzeszów, Warszawa

clinicaltrials.gov/show/NCT01528345
NCT01524926 CREATE: Cross-tumoral Phase 2 With Crizotinib różne nowotwory ALK+ , MET II Pfizer 2012-09 2017-12

Warszawa

clinicaltrials.gov/show/NCT01524926
NCT01506609 The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer rak piersi BRCA1 , BRCA2 II Abbvie 2012-01 2015-12

Bydgoszcz, Nadarzy, Olsztyn, Poznań, Rzeszów

clinicaltrials.gov/show/NCT01506609
NCT01481272 Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients chłoniak wielkokomórkowy II PGCh 2011-02 2013-08

Poznań, Rzeszów, Warszawa, CO-I Warszawa

clinicaltrials.gov/show/NCT01289041
NCT01506609 The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer rak piersi BRCA1 , BRCA2 II Abbvie 2012-01 2015-12

Bydgoszcz, Nadarzy, Olsztyn, Poznań, Rzeszów

clinicaltrials.gov/show/NCT01506609
NCT01453205 A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) chłoniak B-komórkowy nawrót II MedImmune 2012-02 2018-12

Chorzów , Lublin

clinicaltrials.gov/show/NCT01453205
NCT01396148 A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor GIST progresja II Pfizer 2012-06 2019-11

Warszawa

clinicaltrials.gov/show/NCT01396148
NCT01390948 A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma glejak 3-18 r.ż. II Roche 2011-10 2020-03

Warszawa

clinicaltrials.gov/show/NCT01390948
NCT01157806 Palliative Radiochemotherapy Against Palliative Surgery in Stage IV Rectal Cancer With Unresectable Metastases rak odbytu przerzutowy nieoperacyjny II COI Wwa , W.Michalski@coi.waw.pl 2010-01 -

COI Wwa

clinicaltrials.gov/show/NCT01157806
NCT00932451 An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene rak płuca ALK+ II Novartis 2010-01 2015-03

Gdańsk , Olsztyn

clinicaltrials.gov/show/NCT00932451
NCT00772694 Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy rak jądra nieoperacyjny II Wygrajmy Zdrowie 2008-12 -

COI Wwa , i.skoneczna@coi.waw.pl

clinicaltrials.gov/show/NCT00772694
NCT00688623 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe guzy neuroendokrynne nieoperacyjny , przerzutowy II Novartis 2009-06 -

Gdańsk

clinicaltrials.gov/show/NCT00688623
NCT00501332 Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy rak piersi adjuwant TAC II Maxygen 2007-07 -

Gdańsk, Bydgoszcz, Lublin

clinicaltrials.gov/show/NCT00501332
NCT00290667 Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma chłoniak B-komórkowy II GLSG 2004-02 -

Wrocław dr Wróbel

clinicaltrials.gov/show/NCT00290667
NCT00106431 A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-Cell Lymphoma chłoniak II Celgene 2015-01 -

różne

clinicaltrials.gov/show/NCT00106431
NCT02340208 A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 rak płuca niedrobnokomórkowy, niepłaskonabłonkowy II Helix BioPharma Corporation 2012-05 2016-06

Otwock, Poznań COI Warszawa

clinicaltrials.gov/show/NCT02340208
NCT01526928 Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients rak płuca przerzutowy nowotwór II Clovis Oncology 2012-03 2016-02

UM Gdańsk , zakrzewska@gumed.edu.pl

clinicaltrials.gov/show/NCT01526928
NCT00716495 Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma czerniak zaawansowany II AGIRx Limited 2008-06 -

Wielkopolskie Centrum Onkologii, UM Poznań

clinicaltrials.gov/show/NCT00716495
NCT01950273 Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Lymphoma II - IV NHL II - IV NHL I Zakopane 2013-01 -

Zakopane , kosa@mp.pl

clinicaltrials.gov/show/NCT02040662
NCT01772004 MSB0010718C in Solid Tumors guzy lite zaawansowany , przerzutowy I Serono 2013-01 2016-10

Warszawa

clinicaltrials.gov/show/NCT01772004
NCT01519323 BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations czerniak 12-17 r.ż. I Roche 2013-01 2016-05

Wrocław

clinicaltrials.gov/show/NCT01519323
NCT02340208 A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 rak płuca niedrobnokomórkowy, niepłaskonabłonkowy I Helix BioPharma Corporation 2012-05 2016-06

Otwock, Poznań COI Warszawa

clinicaltrials.gov/show/NCT02340208
NCT01526928 Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients rak płuca przerzutowy nowotwór I Clovis Oncology 2012-03 2016-02

UM Gdańsk , zakrzewska@gumed.edu.pl

clinicaltrials.gov/show/NCT01526928
NCT00716495 Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma czerniak zaawansowany I AGIRx Limited 2008-06 -

Wielkopolskie Centrum Onkologii, UM Poznań

clinicaltrials.gov/show/NCT00716495
NCT01180049 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma chłoniak komórki płaszcza IV Pfizer 2011-03 2017-07

Gdańsk, Kraków

clinicaltrials.gov/show/NCT01180049
NCT01216254 Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation rak piersi operacyjny IV GUM 2010-10 -

Gdańsk

clinicaltrials.gov/show/NCT01216254
NCT01894828 Nutritional Supplementation in Patients With no Signs of Malnutrition now. układu pokarmowego pierwotny lub wtórny IV MedSource 2011-04 2010-10

Gdańsk pawel.kabata@gmail.com

clinicaltrials.gov
NCT01909934 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma chłoniak kontynuacja IV Millenium 2013-10 2020-05

Gdańsk, Kraków, Warszawa

clinicaltrials.gov
NCT01990534 A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma chłoniak Hodgikna oporny IV Millenium 2014-03 2019-12

Gdańsk, Kraków, Warszawa

www.clinicaltrials.gov
NCT02236637 A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care rak gruczołu krokowego rak gruczołu krokowego IV Janssen 2013-06 2018-12

Bydgoszcz, Gdynia, Łódź, Opole, Poznań, Warszawa

clinicaltrials.gov
NCT02323659 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas chłoniak komórki płaszcza IV PGCh 2012-04 2013-03

Bydgoszcz

clinicaltrials.gov
NCT01322490 (BNIT-PRV-301) A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer” rak prostaty pacjenci z bezobjawowym lub skapoobjawowym rakiem gruczołu krokowego z przerzutami, opornym na kastrację) III Bavarian Nordic, Inc 2013-12 2014-12

Warszawa - Dr Artur Antoniewicz, Oddział Urologii, Międzyleski Szpital Specjalistyczny, tel: (22) 815 68 61

Warszawa - Dr Iwona Skoneczna. Szpital Św. Elżbiety -Mokotowskie Centrum Medyczne Sp. z o. o., tel: (22) 542 06 00

Siedlce - Dr Adam Marcheluk, Urologica (http://www.urologica.pl/), tel: 510 288 520

Grodzisk Mazowiecki - Dr Marek Filipek , Ameds Centrum (http://www.ameds.pl/), tel: (22) 734 40 34

Wrocław - Prof. Romuald Zdrojowy, Klinika Urologii i Onkologii Urologicznej, Uniwersytecki Szpital Kliniczny we Wrocławiu, tel: (71) 733 10 30, (71) 733 10 10

Dodatkowe informacje w języku polskim

www.clinicaltrials.gov
www.continueyourfight.com
Dodatkowe informacje w języku polskim
NCT01268059 A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer rak płuca nie leczeni I Medimmune 2010-12 2013-12

Gdańsk, Łódź, Mrozy, Szczecin

www.clinicaltrials.gov
NCT01149343 Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer czerniak stopień III i IV I GSK 2010-07 2018-03

Gdańsk, Olsztyn , Poznań Słupsk

www.clinicaltrials.gov
NCT01472887 SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients (STARLYTE) chłoniak B-komórkowy II Sanofi 2012-01 2014-12

Brzozów, Rzeszów , Warszawa

www.clinicaltrials.gov
NCT00688623 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (RAMSETE/CDE16) guzy neuroendokrynne zaawansowany nowotwór II Novartis 2009-06 2012-12

Gdańsk, Warszawa

www.clinicaltrials.gov
NCT01004003 Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma rak wątroby zaawansowany nowotwór II Boehringer Ingelheim 2009-10 2014-01

Olsztyn , Warszawa

www.clinicaltrials.gov
NCT01186861 Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy rak płuca bez progresji II Astellas 2010-12 2012-12

Elbląg, Gdańsk, Gliwice, Rybnik, Łódź

www.clinicaltrials.gov
NCT01441414 PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma rak nerki przerzutowy II Pfizer 2011-11 2014-11

Gdańsk, Wrocław

www.clinicaltrials.gov
NCT01157806 Palliative Radiochemotherapy Against Palliative Surgery in Stage IV Rectal Cancer With Unresectable Metastases rak odbytnicy przerzutowy II CO-I Wwa 2010-01 2012-06

CO-i Wwa W.Michalski@coi.waw.pl, bujko@coi.waw.pl

www.clinicaltrials.gov
NCT01481272 Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients (PLRG8) chłoniak B-komórkowy II Polish Lymmphoma Research Group 2011-11 2016-05

Dolnośląskie Centrum Transplantacji Komórkowych-Wrocłąw, CO-I Wwa epaszkiewicz@coi.waw.pl , IHiT Wwa warzocha@ihit.waw.pl , Brzozów, Gdańsk

www.clinicaltrials.gov
NCT01008475 EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wildtype Metastatic Colorectal Cancer rak jelita grubego przerzutowy II Merck 2009-10 2013-03

Elbląg, Gdańsk, Gliwice, Rybnik, Łódź

www.clinicaltrials.gov
NCT01500720 Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer rak płuca drobnokomórkowy II Sanofi 2012-02 2014-06

Gdańsk, Lublin, Warszawa

www.clinicaltrials.gov
NCT00929188 A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain leczenie wspomagające ból II Janssen 2009-06 2015-06

Bydgoszcz, Gdańsk, Gdańsk-Zaspa, Łódź, Warszawa, Wrocław,

www.clinicaltrials.gov
NCT01136733 A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment rak nerki zaawansowany, nieoperacyjny nowotwór II Eisai 2010-08 2013-09

Gdańsk, Łódź, Szczecin, Warszawa

www.clinicaltrials.gov
NCT01390948 A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma glejak stopień III i IV II Roche 2011-10 2018-01

Warszawa

www.clinicaltrials.gov
NCT01381874 A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy rak piersi ER+, z progresją II Janssen 2011-08 2014-07

Białystok, Gdańsk, Olsztyn, Warszawa,

www.clinicaltrials.gov
NCT01251640 Combination With Gemcitabine in Advanced Pancreatic Cancer (BAGPAC) rak trzuski zaawansowany nowotwór II Bayer 2011-01 2013-08

Białystok, Gdańsk, Warszawa,

www.clinicaltrials.gov
NCT01348126 Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY) rak płuca przerzutowy II Synta 2011-05 2013-02

Kraków, Olsztyn, Prabuty, Szczecin

www.clinicaltrials.gov
NCT00688753 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe (RAPTOR/LFR08) rak nerki przerzutowy nie leczony II Novartis 2009-07 2013-08

Otwock, Warszawa, Wrocław

www.clinicaltrials.gov
NCT01149343 Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer czerniak stopień III i IV II GSK 2010-07 2018-03

Gdańsk, Olsztyn , Poznań Słupsk

www.clinicaltrials.gov
NCT01289041 BKM120 as Second-line Therapy for Advanced Endometrial Cancer rak endometrium po 1 linii II Novartis 2011-02 2013-08

Poznań, Rzeszów, Warszawa, CO-I Warszawa

www.clinicaltrials.gov
NCT01268059 A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer rak płuca nie leczeni II Medimmune 2011-12 2013-12

Gdańsk, Łódź, Mrozy, Szczecin

www.clinicaltrials.gov
NCT01026142 A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) rak piersi przerzutowy HER2+ II Roche 2010-01 2017-08

Brzozów, Lublin, Gdańsk, Elblag, Słupsk

http://clinicaltrials.gov/show/NCT01582269
NCT01582269 A Study in Recurrent Glioblastoma (GB) glejak leczeni II Lilly 2012-04 2014-08

Białystok, Łódź, Olsztyn

www.clinicaltrials.gov
NCT00839332 A Study for Patients With Pancreatic Cancer rak trzuski nieoperacyjny II Lilly 2009-03 2013-05

Warszawa

www.clinicaltrials.gov
NCT00889382 A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) rak jajnika choroba progresująca II Astellas 2009-07 2013-06

Onkologia Ginekologiczna Lublin, UM Radioterapia Poznań, UM Onkologia Poznań

www.clinicaltrials.gov
NCT01454089 A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer rak pęcherza przerzutowy nie leczony II OncoGenex 2011-10 2014-06

CO Bydgoszcz, Otwock, CO-I Warszawa, UCK Gdańsk, Olsztyn

www.clinicaltrials.gov
NCT01630226 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland rak piersi BRCA1 II Pomeranian Medical University Szczecin 2007-06 2013-12

Szczecin Tomasz Byrski, MD, PhD 48-501-225-501 tomekbyr@wp.pl ; CO-I Warszawa ; Bielsko-Biała

www.clinicaltrials.gov
NCT01450761 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone rak płuca drobnokomórkowy III BMS 2012-01 2016-09

Elbląg, Gdańsk, Katowice, Kraków, Lublin, Otwock, Poznań, Toruń, Warszawa, Wrocław

www.clinicaltrials.gov
NCT01348126 Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY) rak płuca IIIB, IV, NDRP III Synta 2011-05 2013-02

Kraków, Olsztyn, Prabuty, Szczecin

www.clinicaltrials.gov
NCT01704716 High Risk Neuroblastoma Study 1 (1.5) of SIOP-Europe (SIOPEN) neuroblastoma III St. Anna Kinderkrebsforschung 2012-02 2014-12

Białystok, Bydgoszcz, Chorzów, Gdańsk, Kraków, Katowice, Lublin, Poznań, Warszawa, Wrocław

www.clinicaltrials.gov
NCT01265849 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity (IT-MATTERS) rak Jamy ustnej rak płaskonabłonkowy III CEL-SCI Corporation 2010-10 2015-05

Gliwice, Łódź, Kielce, Warszawa CO-I

www.clinicaltrials.gov
NCT01597908 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v) czerniak zaawansowany, nieoperacyjny nowotwór III GSK 2012-06 2015-06

Gdańsk, Konin, Poznań, Warszawa

www.clinicaltrials.gov
NCT01339260 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting leczenie wspomagające przeciwymiotne III Helsinn Healthcare 2011-04 2012-12

CO-I Wwa, Białystok, Elbląg, Kościerzyna, Łomża, Olsztyn, Racibórz, Słupsk, Magodent Wwa, Łodź

www.clinicaltrials.gov
NCT01566721 A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer) rak piersi adjuwant III Roche 2012-09 2019-09

Kraków, Otwock, Olsztyn, Poznań, Rzeszów, Żory

www.clinicaltrials.gov
NCT01361607 Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III) leczenie wspomagające zaawansowany nowotwór III GW Pharmaceuticals 2011-05 2014-02

Bydgoszcz, Gdańsk, Kłodzko, Ostrowiec, Wrocław, Żory

www.clinicaltrials.gov
NCT01327885 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma mięsak zaawansowany nowotwór III Eisai 2011-04 2015-03

Gdańsk, Gliwice, Warszawa

www.clinicaltrials.gov
NCT01395914 Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3) rak płuca kontynuacja poprzedniego badania III Helsinn Healthcare 2011-07 2013-07

Bydgoszcz, Kraków, Łódź, Lublin

www.clinicaltrials.gov
NCT01419197 A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA) rak piersi przerzutowy HER2+ III Genentech 2011-09 2015-04

Białystok, Bydgoszcz, Gdańsk, Lublin, Poznań

www.clinicaltrials.gov
NCT01358877 A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer rak piersi leczenie adjuwantowe III Roche 2011-11 2024-08

Białystok, Bydgoszcz, Gdańsk, Kraków, Łódź, Lublin, Opole, Warszawa, Wieliszew

www.clinicaltrials.gov
NCT01450696 A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer rak żołądka przerzutowy HER2+ III Roche 2012-11 2020-06

Kraków, Lublin, CO-I Warszawa

www.clinicaltrials.gov
NCT01328951 A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy rak płuca zaawansowany nowotwór III Roche 2011-09 2016-06

Brzozów, Kraków, Poznań, Zamość

www.clinicaltrials.gov
NCT01168973 A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy rak płuca po 1 linii III Lilly 2010-12 2015-04

Gdańsk, Gdynia, Głuchołazy, Kraków, Łódź, Opole, Otwock, Poznań

www.clinicaltrials.gov
NCT01168973 A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy rak płuca po 1 linii III Lilly 2010-12 2015-04

Gdańsk, Gdynia, Głuchołazy, Kraków, Łódź, Opole, Otwock, Poznań

www.clinicaltrials.gov
NCT01454934 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer rak płuca zbadany EGFR III Eisai 2011-09 2014-10

Gdańsk, Mrozy, Otwock, Szczecin, Warszawa

www.clinicaltrials.gov
NCT01180049 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma chłoniak Mantle cell IV Pfizer 2011-03 2015-04

Kraków : Malopolskie Centrum Medyczne S.C.

clinicaltrials.gov
NCT01216254 Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation rak piersi operacyjny IV GUMED 2010-10 2013-10

Jacek Zielinski,

+48583492440,

jaziel@gumed.edu.pl

clinicaltrials.gov
NCT00878709 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer rak piersi post-adjuwant III Pfizer 2009-06 2013-09

Bydgoszcz; Gdańsk; Gdynia; Kraków; Olsztyn; Tarnów

www.clinicaltrials.gov
NCT01212991 A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer rak prostaty zaawansowany/przerzutowy III Astellas 2010-09 2014-09

Mysłowice; Poznań; Wrocław

www.clinicaltrials.gov
NCT01151215 Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer rak piersi zaawansowany/przerzutowy II AstraZeneca 2010-06 2015-08

Białystok; Elbląg; Gdynia; Kraków; Warszawa

www.clinicaltrials.gov
NCT00375674 A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer rak nerki po resekcji/uzupełniająco III Pfizer 2007-07 2017-06

Łódź; Poznań; Warszawa; Kraków

www.clinicaltrials.gov
www.clinicaltrials.gov
NCT00688623 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe guzy neuroendokrynne zaawansowany/przerzutowy II Novartis 2009-09 2012-03

Gdańsk

www.clinicaltrials.gov
NCT01285609 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin rak płuca 1. linia III BMS 2011-06 2016-06

Elbląg; Gdańsk; Olsztyn; Szczecin

www.clinicaltrials.gov
NCT01234337 Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer rak piersi miejscowo zaawansowany lub przerzutowy HER2-ujemny III Bayer 2011-02 2012-08

Gdańsk; Gdynia; Poznań

www.clinicaltrials.gov
NCT01360554 ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer n. rak płuca po 1. lub 2. linii IIIB/IV III Pfizer 2011-06 2013-02

Otwock; Warszawa

www.clinicaltrials.gov
NCT00858364 Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy n. rak płuca po 1. linii III Amgen 2009-09 2019-06

Bydgoszcz; Łomża; Olsztyn; Rzeszów; Suwałki; Szczecin; Warszawa; Wrocław

www.clinicaltrials.gov
NCT01360840 EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer rak gruczołu krokowego hormonooporny II Serono 2011-04 2013-10

Gdańsk

www.clinicaltrials.gov
NCT01217697 Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer rak gruczołu krokowego leczenie bifosfonianami III J&J 2010-11 2014-10

Gdańsk; Łódź; Opole; Otwock; Wrocław

www.clinicaltrials.gov
NCT01308567 Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer rak gruczołu krokowego zaawansowany nowotwór III Sanofi 2011-05 2017-12

Bydgoszcz; Gdańsk; Kościerzyna; Łódź; Poznań

www.clinicaltrials.gov
NCT01308580 Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer rak gruczołu krokowego hormonooporny przerzutowy III Sanofi 2011-04 2017-09

Olsztyn; Rybnik; Siedlce

www.clinicaltrials.gov
NCT00925600 A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy rak gruczołu krokowego hormonooporny przerzutowy III Amgen 2009-11 2014-02

Gdańsk; Gdynia; Katowice; Mysłowice; Opole; Poznań; Szczecin; Warszawa; Wrocław

www.clinicaltrials.gov
NCT00790036 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy DLBCL III/IV stopień, CR po chemioterapii z rytuksymabem III Novartis 2009-07 2014-05

Bydgoszcz; Łódź; Lublin; Warszawa

www.clinicaltrials.gov
NCT00209209 Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL chłoniak płaszcza 1. linia leczenia III University of Cologne 2004-01 2014-01

CO-I Warszawa Jan Walewski; Ph: +48-22-546-2223; walewski@coi.waw.pl

www.clinicaltrials.gov
NCT01004003 Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma rak wątroby przerzutowy II Boehringer Ingelheim 2009-10 2013-02

Warszawa

www.clinicaltrials.gov
NCT00643565 A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma. II Sponsor Roche 2008-07 2019-11

Warszawa

www.clinicaltrials.gov
NCT01523015 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction rak żołądka operacyny III UM Lublin 2012-01 2020-12

UM Lublin Tomasz Skoczylas, MD, PhD; Ph: +48 81 5328810, Email: tomskocz@yahoo.com

www.clinicaltrials.gov
NCT01285557 Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial rak żołądka operacyjny III Taiho Pharma 2011-02 2014-08

Gdańsk; Szczecin; Łódź; Warszawa

www.clinicaltrials.gov
NCT01170663 A Study of Paclitaxel With or Without Ramucirumab in Metastatic Gastric Adenocarcinoma rak żołądka przerzutowy nie leczony III ImClone 2010-10 2013-12

Bydgoszcz; Brzozów; Łódź; Lublin; Poznań; Warszawa

www.clinicaltrials.gov
NCT01395017 Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer rak trzustki II Otsuka 2011-06 2014-08

Lublin; Olsztyn

www.clinicaltrials.gov
NCT01186861 Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy rak płuca zaawansowany nowotwór II Astellas 2010-12 2012-12

Instytut Gruźlicy i Chorób Płuc,
I Klinika Chorób Płuc Warszawa;
Szczecin Zdunowo;
Elbląg; Toruń;
Wrocław;
CO-I Warszawa

www.clinicaltrials.gov
NCT01185847 A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer rak płuca ALK+ II Roche 2010-11 2013-12

Łódź; Otwock

www.clinicaltrials.gov
NCT01160744 A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC) rak płuca zaawansowany nowotwór II ImClone 2010-09 2014-12

Gdańsk; Kościerzyna; Warszawa

www.clinicaltrials.gov
NCT01387282 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2) n. rak płuca zaawansowany nowotwór III Helsinn Healthcare 2011-07 2013-07

Bydgoszcz; Grudziądz; Katowice; Kraków; Łódź; Lublin; Szczecin; Warszawa

www.clinicaltrials.gov
NCT01098266 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed międzybłoniak opłucnej 1sza linia leczenia III MolMed 2010-03 2013-02

UCK Gdańsk - Jacek Jassem;
CO-I Warszawa - Paweł Badurak

www.clinicaltrials.gov
NCT01077154 Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) rak piersi wczesny III Amgen 2010-05 2021-10

Gdańsk; Kraków; Olsztyn; Poznań; Rzeszów; Szczecin

www.clinicaltrials.gov
NCT00081796 Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer rak piersi zaawansowany/przerzutowy HER2+ III Sanofi 2004-04 2006-09

Kraków;
Warszawa

www.clinicaltrials.gov
NCT01160211 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer rak piersi przerzutowy III GSK 2011-05 2017-12

Konin; Lubin; Otwock; Warszawa; Wieliszew; Wrocław

www.clinicaltrials.gov
NCT00738790 Preoperative Radiotherapy and Local Excision in Rectal Cancer rak odbytnicy radioterapia przedoperacyjna III CO-I Warszawa 2003-11 2013-11

Krzysztof Bujko;
Ph: +48226439287;
bujko@coi.waw.pl

www.clinicaltrials.gov
NCT01235962 A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) rak nerki pooperacyjny III GSK 2010-11 2017-04

Gdańsk; Konin; Kraków; Warszawa; Lublin; Wrocław

www.clinicaltrials.gov
NCT00883792 The Northern-European Initiative on Colorectal Cancer rak jelita skrining III Norwegian Ministry of Health 2009-05 2036-07

CO-I Warszawa - Jaroslaw Regula, MD PhD Ph: 48 606 906 992, jregula@coi.waw.pl

www.clinicaltrials.gov
NCT01001377 ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer rak jelita grubego przerzutowy/chemiooporny III Amgen 2010-02 2013-08

Elbląg; Gdańsk; Jelenia Góra; Poznań; Szczecin; Warszawa

www.clinicaltrials.gov
NCT01204749 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer rak jajnika po operacji III Amgen 2010-10 2017-04

Bydgoszcz; Gdańsk; Lublin; Poznań; Warszawa

www.clinicaltrials.gov
NCT00772694 Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy rak jądra chemiooprny nawrotowy/nieoperacyjny II Fondation Wygrajmy Zdrowie 2008-09 2011-12

CO-I Warszawa, Iwona Skoneczna; Ph: +48225462098; i.skoneczna@coi.waw.pl

www.clinicaltrials.gov
NCT01535209 Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection przerzuty do mózgu po resekcji pojedynczego ogniska III CO-I Warszawa 2012-01 2014-12

CO-I Warszawa - Lucyna Kępka; Ph: 0048506118893; lucynak@coi.p

www.clinicaltrials.gov
NCT01363479 An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting guzy lite nieleczeni III Helsinn Healthcare 2011-06 2012-06

Elbląg; Łódź; Łomża; Warszawa CO-I, Magodent

www.clinicaltrials.gov
NCT00634049 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi przecigrzybicze leczenie III Astellas 2008-04 2012-07

Warszawa

www.clinicaltrials.gov
NCT00412893 Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis przecigrzybicze leczenie III Astellas 2006-12 2012-07

Warszawa; Chorzów

www.clinicaltrials.gov
NCT01147809 Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag guzy lite leczenie wspomagające II GSK 2010-06 2013-09

Poznań; Konin

www.clinicaltrials.gov
NCT00625378 Sorafenib Long Term Extension Program (STEP) guzy lite kontynuacja III Bayer 2007-12 2014-07

Gdańsk; Poznań; Szczecin; Warszawa; Wrocław

www.clinicaltrials.gov
NCT01130025 Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer aktywna choroba nowotworowa objawowa zakrzepica III Leo Pharma 2010-08 2012-12

Nasielsk; Opole; Warszawa; Wrocław

www.clinicaltrials.gov
NCT01450449 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme GBM noworozpoznany >50 lat III International Atomic Energy Agency 2009-02 2013-03

CO-I Warszawa - Lucyna Kępka; Ph: 0048506118893; lucynak@coi.p

www.clinicaltrials.gov
NCT00110123 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma czerniak gałki ocznej przerzutowy III EORTC 2005-01 2010-12

CO-I Warszawa Ph: 48-22-644-0200

www.clinicaltrials.gov
NCT00290667 Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma chłoniak B-komórkowy nie leczeni II German High-Grade Non-Hodgkin's Lymphoma Study Group 2004-02 2013-12

Wrocław

www.clinicaltrials.gov
NCT00937183 Phase I/II Study of Adjuvant Dendritic Cell-Lymphoma Cell Hybrids and/or Dendritic Cells Pulsed With Tumor Lysates in Patients With Indolent B-Cell Lymphoma or Multiple Myeloma chłoniak B-komórkowy bez progresji II CO-I Warszawa 2003-09 2010-06

CO-I Warszawa, Jan Walewski, MD Ph: 48-22-546-2223 walewski@coi.waw.pl

www.clinicaltrials.gov
NCT01077518 Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen chłoniak B-komórkowy oporny na rituksymab III GSK 2010-08 2022-05

Gdynia; Warszawa; Wrocław

www.clinicaltrials.gov
NCT01100502 A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) chłoniak Hodgkina po przeszczepie III Seattle Genetics 2010-04 2016-04

Klinika Hematologii UCK Gdańsk,

Marcelina Paruch,

Ph: +48 22 210 02 00 (01) ext.4864, marcelina.paruch@psi-cro.com;

Gliwice; Katowice; Kraków; Lublin;Łódź; Warszawa

www.clinicaltrials.gov
NCT00209222 Efficacy of Rituximab - Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus R-CHOP/R-DHAP in Patients With Untreated Mantle Cell Lymphoma chłoniak płaszcza 1sza linia leczenia III University of Cologne 2004-07 2010-06

Jan Walewski;

Ph: +48-22-546-2223;

walewski@coi.waw.pl

www.clinicaltrials.gov
NCT01232556 A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy NHL oporny/nawrotowy III Pfizer 2011-04 2015-12

Warszawa

www.clinicaltrials.gov
NCT00646854 Alemtuzumab and CHOP in T-cell Lymphoma chłoniak T-kom 1sza linia leczenia III Aarhus Universitetshospital 2008-06 2016-12

CO-I Warszawa; prof.J.Walewski, walewski@coi.waw.pl

www.clinicaltrials.gov
NCT00822614 Safety of Fentanyl TAIFUN Treatment choroba nowotworowa ból przebijający III Akela Pharma 2008-12 2010-01

Zbigniew Kaczmarek - Włocławek

www.clinicaltrials.gov
NCT01337089 Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain kontynuacja poprzedniego badania III GW Pharmaceuticals 2011-01 2014-08

Bielsko-Biała; Gliwice; Poznań; Warszawa

www.clinicaltrials.gov
NCT00472303 A Study to Evaluate CG5503 in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine ból nowotworowy zaawansowany nowotwór III Grunenthal 2007-07 2012-04

Bydgoszcz; Warszawa

www.clinicaltrials.gov
NCT01262651 A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer ból nowotworowy zaawansowany nowotwór III GW Pharmaceuticals 2010-12 2012-03

Białystok; Bielsko-Biała; Gdańsk; Gliwice; Poznań; Warszawa

www.clinicaltrials.gov